Peoples Bank KS Acquires Shares of 4,895 Cencora, Inc. (NYSE:COR)

Peoples Bank KS bought a new stake in Cencora, Inc. (NYSE:COR) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor bought 4,895 shares of the company’s stock, valued at approximately $1,102,000.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. purchased a new stake in Cencora during the fourth quarter valued at about $4,212,508,000. Price T Rowe Associates Inc. MD bought a new position in Cencora in the 1st quarter worth approximately $2,183,619,000. JPMorgan Chase & Co. bought a new position in Cencora in the 1st quarter worth approximately $1,199,695,000. Boston Partners purchased a new position in Cencora in the 1st quarter valued at approximately $1,001,269,000. Finally, Capital Research Global Investors bought a new stake in Cencora during the 1st quarter valued at $650,424,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Trading Down 0.5 %

NYSE:COR traded down $1.02 during midday trading on Friday, reaching $219.94. 1,638,139 shares of the stock traded hands, compared to its average volume of 1,415,768. The company has a fifty day moving average of $234.76 and a 200 day moving average of $232.34. Cencora, Inc. has a 12 month low of $182.62 and a 12 month high of $247.66. The stock has a market capitalization of $43.87 billion, a P/E ratio of 24.18, a PEG ratio of 1.58 and a beta of 0.44. The company has a debt-to-equity ratio of 3.93, a quick ratio of 0.55 and a current ratio of 0.89.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.18 by $0.16. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The company had revenue of $74.20 billion for the quarter, compared to the consensus estimate of $73.32 billion. During the same quarter in the previous year, the business earned $2.92 EPS. Cencora’s revenue was up 10.8% compared to the same quarter last year. On average, research analysts predict that Cencora, Inc. will post 13.63 EPS for the current year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 9th were paid a $0.51 dividend. The ex-dividend date was Friday, August 9th. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.93%. Cencora’s dividend payout ratio is currently 22.32%.

Insider Activity at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,473 shares of Cencora stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total value of $357,482.37. Following the completion of the sale, the executive vice president now owns 10,948 shares of the company’s stock, valued at approximately $2,656,970.12. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, EVP Silvana Battaglia sold 1,473 shares of the firm’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total value of $357,482.37. Following the sale, the executive vice president now owns 10,948 shares in the company, valued at approximately $2,656,970.12. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Steven H. Collis sold 10,755 shares of the company’s stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $222.12, for a total value of $2,388,900.60. Following the sale, the chief executive officer now owns 285,088 shares of the company’s stock, valued at approximately $63,323,746.56. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 4,450,399 shares of company stock valued at $1,070,392,799. 15.80% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on COR shares. Wells Fargo & Company lifted their price target on Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a research report on Thursday, August 1st. JPMorgan Chase & Co. raised their price objective on shares of Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research report on Wednesday, August 21st. StockNews.com lowered shares of Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. Robert W. Baird decreased their price target on shares of Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a report on Friday, September 6th. Finally, Bank of America restated a “neutral” rating and set a $245.00 target price (down from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $256.67.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.